Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer.
To evaluate the efficacy and safety of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer. 92 patients with cervical cancer in moderate and advanced stages treated in Shanghai Public Health Clinical Center from January 2014 to January 2017 were selected and divided into two groups with 46 cases in each group. They received cisplatin and nimotuzumab combined with concurrent chemoradiotherapy and cisplatin combined with concurrent chemoradiotherapy, respectively. The clinical efficacy, adverse reactions, overall survival (OS) and progression-free survival (PFS) were compared between the two groups. The general clinical characteristics of patients in both groups were comparable. The effective rate was 87.0% and 67.4%, respectively, in nimotuzumab group and cisplatin group, and the local tumor control and short-term efficacy were superior in the nimotuzumab group compared to those in the cisplatin group (p=0.045). There was no statistically significant difference in the incidence of complications after treatment between the two groups (p>0.05), and nimotuzumab did not increase the incidence and severity of adverse reactions. The 3-year OS rate was 87.0% (40/46) and 69.6% (32/46), respectively, in the two groups (log-rank, p=0.070). The 3-year PFS rate in the nimotuzumab group [73.9% (34/46)] was obviously higher than that in the cisplatin group [50.0% (23/46)] (p=0.042). Cisplatin and nimotuzumab combined with concurrent chemoradiotherapy is safe and effective in the treatment of locally advanced cervical cancer, both local tumor control and PFS rate are excellent, and the patient's tolerance is good, so it is worth of clinical popularization.